Skip to main content
SpringerLink
Log in

Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report

  • Case report
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Diffuse brainstem glioma carries a dismal prognosis. The current cornerstone of treatment is radiation therapy. Chemotherapy appears to be ineffective and the role of this treatment in the recurrent or progressive setting is not known. Bevacizumab and irinotecan have been reported to have shown radiographic response and improvement in progression-free survival among patients with malignant supratentorial gliomas. In this paper, we report our experience in an adult patient with progressive diffuse brainstem glioma treated with bevacizumab and irinotecan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Packer RJ (1999) Brain tumors in children. Arch Neurol 56(4):421–425. doi:10.1001/archneur.56.4.421

    Article  PubMed  CAS  Google Scholar 

  2. Freeman CR, Farmer JP (1998) Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 40(2):265–271. doi:10.1016/S0360-3016(97)00572-5

    PubMed  CAS  Google Scholar 

  3. Rubin G, Michowitz S, Horev G, Herscovici Z, Cohen IJ, Shuper A, Rappaport ZH (1998) Pediatric brain stem gliomas: an update. Childs Nerv Syst 14(4–5):167–173. doi:10.1007/s003810050205

    Article  PubMed  CAS  Google Scholar 

  4. Guillamo JS, Monjour A, Taillandier L, Devaux B, Varlet P, Haie-Meder C, Defer GL, Maison P, Mazeron JJ, Cornu P, Delattre JY, Association des Neuro-Oncoloques d’Expression Francoise (ANOCEF) (2001) Brainstem gliomas in adults: prognostic factors and classification. Brain 124(Pt 12):2528–2539. doi:10.1093/brain/124.12.2528

    Article  PubMed  CAS  Google Scholar 

  5. Massimino M, Spreafico F, Biassoni V, Simonetti F, Riva D, Trecate G, Giombini S, Poggi G, Pecori E, Pignoli E, Casanova M, Ferrari A, Meazza C, Luksch R, Terenziam M, Cefalo G, Podda M, Polastri D, Clerici CA, Fossati-Bellani F, Gondola L (2008) Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 87(3):355–361. doi:10.1007/s11060-008-9525-5

    Article  PubMed  CAS  Google Scholar 

  6. Landolfi JC, Thaler HT, DeAngelis LM (1998) Adult brainstem gliomas. Neurology 51(4):1136–1139

    PubMed  CAS  Google Scholar 

  7. Selvapandian S, Rajshekhar V, Chandy MJ (1999) Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien) 141(7):721–726. doi:10.1007/s007010050367 (discussion 726–727)

    Article  CAS  Google Scholar 

  8. Epstein F, Constantini S (1996) Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 24(1):24–34. doi:10.1159/000121011

    Article  PubMed  CAS  Google Scholar 

  9. Schild SE, Stafford SL, Brown PD, Wood CP, Scheithauer BW, Schombert PJ, Wong WW, Lyons MK, Shaw EG (1998) The results of radiotherapy for brainstem tumors. J Neurooncol 40(2):171–177. doi:10.1023/A:1006193306286

    Article  PubMed  CAS  Google Scholar 

  10. Freeman CR, Perilongo G (1999) Chemotherapy for brain stem gliomas. Childs Nerv Syst 15(10):545–553. doi:10.1007/s003810050542

    Article  PubMed  CAS  Google Scholar 

  11. Shuper A, Kornreich L, Loven D, Michowitz S, Schwartz M, Cohen IJ (1998) Diffuse brain stem gliomas. Are we improving outcome? Childs Nerv Syst 14(10):578–581. doi:10.1007/s003810050275

    Article  PubMed  CAS  Google Scholar 

  12. Bouffet E, Khelfaoui F, Philip I, Biron P, Brunet-Mentigny M, Philip T (1997) High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 39(4):376–379. doi:10.1007/s002800050586

    Article  PubMed  CAS  Google Scholar 

  13. Allen JC, Siffert J (1996) Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg 24(2):98–102. doi:10.1159/000121024

    Article  PubMed  CAS  Google Scholar 

  14. Wolff JE, Westphal S, Molenkamp G, Gnekow A, Warmuth-Metz M, Rating D, Kuehl J (2002) Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87(9):945–949. doi:10.1038/sj.bjc.6600552

    Article  PubMed  CAS  Google Scholar 

  15. Vredenburgh JJ, Desjardins A, Herndon JEII, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259. doi:10.1158/1078-0432.CCR-06-2309

    Article  PubMed  CAS  Google Scholar 

  16. Vredenburgh JJ, Desjardins A, Herndon JEII, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729. doi:10.1200/JCO.2007.12.2440

    Article  PubMed  CAS  Google Scholar 

  17. Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, hiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:91s (abstr 2010b)

    Google Scholar 

  18. Gururangan S, Chi S, Onar A, Packer R, Young Poussaint T, Gilbertson R, Friedman H, Kun L, Boyett J (2008) Phase II study of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma—a Pediatric Brain Consortium Study (PBTC-022). Neuro Oncol 5:833 (abstract MA-63)

    Google Scholar 

  19. Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197–206. doi:10.1634/theoncologist.9-2-197

    Article  PubMed  Google Scholar 

  20. Lu C, Shervington A (2008) Chemoresistance in gliomas. Mol Cell Biochem 312:71–80. doi:10.1007/s11010-008-9722-8

    Article  PubMed  CAS  Google Scholar 

  21. Reddy A, Mapstone T (2000) Brain stem tumors. In: Bernstein M, Berger MS (eds) Neuro-oncology the essentials. Thieme Medical Publishers, Inc, New York, pp 352–386

    Google Scholar 

  22. Packer RJ, Prados M, Phillips P, Nicholson HS, Bovett JM, Goldwein J, Rorke LB, Needle MN, Sutton L, Zimmerman RA, Fitz CR, Vezina LG, Etcubanas E, Wallenberg JC, Reaman G, Wara W (1996) Treatment of children with newly diagnosed brainstem gliomas with intravenous recombinant beta-inteferon and hyperfractionated radiation therapy: a Childrens Cancer Group phase I/II study. Cancer 77:2150–2156. doi:10.1002/(SICI)1097-0142(19960515)77:10<2150::AID-CNCR28>3.0.CO;2-T

    Article  PubMed  CAS  Google Scholar 

  23. Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goulmnerova L, Billett AL, Kieran M, Tarbell NJ (2003) A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 55(5):1182–1185. doi:10.1016/S0360-3016(02)04391-2

    PubMed  Google Scholar 

  24. Findlay JL, Zacharoulis S (2005) The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical- and futuristic-perspective. J Neurooncol 75:253–266. doi:10.1007/s11060-005-6747-7

    Article  Google Scholar 

  25. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumors. Nat Rev Neurosci 8(8):610–622. doi:10.1038/nrn2175

    Article  PubMed  CAS  Google Scholar 

  26. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19(4(Suppl 3)):7–16 (Williston Park)

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Henry Ford Health System, Hermelin Brain Tumor Center, Detroit, MI, USA

    Roy Torcuator, Richard Zuniga & Tom Mikkelsen

  2. Henry Ford Health System, Hermelin Brain Tumor Center, 2799 W Grand Blvd, Detroit, MI, 48202, USA

    Roy Torcuator & Tom Mikkelsen

  3. Department of Medical Oncology, Henry Ford Health System, Hermelin Brain Tumor Center, Detroit, MI, USA

    Randa Loutfi

  4. Department of Neurology, Henry Ford Health System, Hermelin Brain Tumor Center, Detroit, MI, USA

    Tom Mikkelsen

Authors
  1. Roy Torcuator
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Zuniga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Randa Loutfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tom Mikkelsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roy Torcuator.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torcuator, R., Zuniga, R., Loutfi, R. et al. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report. J Neurooncol 93, 409–412 (2009). https://doi.org/10.1007/s11060-008-9782-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9782-3

Keywords

Search

Navigation